<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717988</url>
  </required_header>
  <id_info>
    <org_study_id>OSCO-P1201</org_study_id>
    <nct_id>NCT02717988</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oscotec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oscotec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, placebo-controlled, single ascending dose study is designed to demonstrate&#xD;
      safety, tolerability and pharmacokinetics of SKI-O-703 in healthy volunteers. The results of&#xD;
      this study will guide selection of dose levels for future multiple dose studies in healthy&#xD;
      volunteers and adult patients with moderately to severely active rheumatoid arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled study in healthy adult volunteers that will be&#xD;
      conducted to evaluate the safety, tolerability, and pharmacokinetics of ascending single&#xD;
      doses of SKI-O-703. A total of 48 subjects are planned to participate in 6 cohorts (8&#xD;
      subjects each). In each cohort, 6 subjects will be randomly assigned to receive SKI-O-703 and&#xD;
      2 subjects will be randomly assigned to matching placebo. Dosing will be initiated in the 50&#xD;
      mg dose cohort and sequentially escalated to the 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg&#xD;
      cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants (Healthy Volunteers) with reported adverse events receiving single dose of SKI-O-703 as assessment of safety and tolerability.</measure>
    <time_frame>28 days</time_frame>
    <description>Safety and tolerability of SKI-O-703 as measured by subject incidence of treatment-related Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time 0 to the last quantifiable concentration (AUC0-t) for estimating the pharmacokinetic parameters of SKI-O-592 (the free base of SKI-O-703) and its metabolites.</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>AUC0-t will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>AUC0-inf will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Days 0 (pre-dose), 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Cmax will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 0 (pre-dose), Day1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Tmax will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (T1/2)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>T1/2 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F) (SKI-O-592, free base of SKI-O-703)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Vd/F will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) (SKI-O-592 only)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>CL/F will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Kel)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Kel will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>MRT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio (Rmet), calculated as AUC0-t (metabolite) / AUC0-t (parent) (metabolites M1, M2 and M4 only).</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (dosing) and post-dose at Days 2, 3 and 4</time_frame>
    <description>Rmet will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (SKI-O-592, free base of SKI-O-703 only)</measure>
    <time_frame>Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Renal clearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of drug excreted in urine over the collection intervals of 0 to 4 hours (Ae0-4), 4 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 48 hours, and 48 to 72 hours post dose.</measure>
    <time_frame>Day 1 (dosing), and post-dose at days 2, 3 and 4</time_frame>
    <description>Ae will be reported</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The pharmacodynamics variable will be the change in the percentage of activated gp53/CD63+ basophils and will be evaluated from serial blood samples collected from subjects who have received SKI-O-703 or placebo.</measure>
    <time_frame>Pre-dose, Day 1(dosing) and post-dose at Day 2</time_frame>
    <description>changes in the percentage of activated gp53/CD63+ basophils will be reported</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SKI-O-703 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (2x25 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (4x25 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (1x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (2x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (3x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKI-O-703 capsule (4x200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI-O-703 capsule</intervention_name>
    <description>SKI-O-703 25 mg capsule or 200 mg capsule without excipient</description>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_label>SKI-O-703 50 mg</arm_group_label>
    <arm_group_label>SKI-O-703 600 mg</arm_group_label>
    <arm_group_label>SKI-O-703 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo 180 mg capsule filled with microcrystalline cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent for participation prior to&#xD;
             completing any study procedures&#xD;
&#xD;
          -  Considered by the investigator to be in good health as determined by the absence of&#xD;
             clinically significant diseases or clinically significant abnormal values as&#xD;
             determined by a detailed medical history review, complete physical examination, and&#xD;
             clinical laboratory assessments. Clinical significance for any out-of-range laboratory&#xD;
             test results will be determined by the principal investigator&#xD;
&#xD;
          -  Male subjects and female subjects of non-childbearing potential between the ages of 18&#xD;
             and 55 years, inclusive&#xD;
&#xD;
          -  Female subjects of non-childbearing potential are those who are surgically sterile at&#xD;
             least 6 months or postmenopausal at least 2 years and have follicle-stimulating&#xD;
             hormone serum levels consistent with postmenopausal status.&#xD;
&#xD;
          -  Male subjects must agree to use a condom with spermicide or abstain from sexual&#xD;
             intercourse for 90 days after dosing&#xD;
&#xD;
          -  Male subjects must agree not to donate sperm for 90 days after dosing&#xD;
&#xD;
          -  Female subjects must have negative serum pregnancy test results at Screening and Day&#xD;
             -1&#xD;
&#xD;
          -  Subject must have a body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive, and&#xD;
             weight ≥50 kg&#xD;
&#xD;
          -  Subject must be able to understand the study and any risks to participation and able&#xD;
             to communicate with the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant disease or disorder that may put the subject at&#xD;
             risk if he/she participates in the study, might affect the subject's ability to&#xD;
             participate in the study, or influence the study results&#xD;
&#xD;
          -  History or presence of any gastrointestinal, hepatic or renal disease, or any other&#xD;
             condition known to interfere with the absorption, distribution, metabolism, or&#xD;
             excretion (ADME) of drugs&#xD;
&#xD;
          -  Any surgical or medical conditions possibly affecting drug ADME (eg, bariatric&#xD;
             procedure)&#xD;
&#xD;
          -  Any medical/surgical procedure or trauma within 4 weeks of Day -1 as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Any clinically significant infection within 3 months of Day -1 as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Any of the following abnormal laboratory values upon repeat testing at Screening or&#xD;
             check-in:&#xD;
&#xD;
               -  Hemoglobin &lt;the lower limit of normal (LLN)&#xD;
&#xD;
               -  Platelet count &lt;LLN&#xD;
&#xD;
               -  Absolute neutrophil count &lt;LLN or &gt;the upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;ULN&#xD;
&#xD;
               -  Creatinine or blood urea nitrogen &gt;ULN&#xD;
&#xD;
               -  Other clinically significant abnormal laboratory results in the opinion of the&#xD;
                  investigator&#xD;
&#xD;
          -  Use of concomitant medications from 30 days or 5 half-lives prior to Day -1 (whichever&#xD;
             is longer), including prescription medications, nutritional supplements, herbal&#xD;
             remedies, and over-the-counter medications&#xD;
&#xD;
          -  Receipt of any investigational medication within 30 days or 5 half-lives prior to Day&#xD;
             -1, whichever is longer&#xD;
&#xD;
          -  Use of tobacco or nicotine-containing products within 30 days prior to Day -1 and&#xD;
             through the End-of-Study visit&#xD;
&#xD;
          -  Use of cytochrome P450 3A isozyme (CYP3A) inducers and inhibitors (including St.&#xD;
             John's wort) within 30 days of dosing&#xD;
&#xD;
          -  Food or beverage containing alcohol, grapefruit or grapefruit juice, apple or orange&#xD;
             juice, vegetables from the mustard green family (eg, kale, broccoli, watercress,&#xD;
             collard greens, kohlrabi, brussels sprouts, mustard), and charbroiled meats within 1&#xD;
             week prior to dosing&#xD;
&#xD;
          -  History of substance abuse, drug addiction, or alcoholism&#xD;
&#xD;
          -  Positive urine drug or urine alcohol test result at screening or Day -1 or unable to&#xD;
             abstain from alcohol from 72 hours prior to study entry to the End-of-Study visit&#xD;
&#xD;
          -  Unable to abstain from caffeine and xanthine-containing products from 72 hours prior&#xD;
             to dosing through discharge from the study site&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating or have a positive serum pregnancy test&#xD;
             result at Screening&#xD;
&#xD;
          -  Positive test results at Screening for human immunodeficiency virus, hepatitis B&#xD;
             surface antigen (HBsAg), hepatitis C virus antibody, or hepatitis B core antibody and&#xD;
             negative for HBsAg&#xD;
&#xD;
          -  Recent (past 5 years) history of malignancy except successfully treated basal cell&#xD;
             carcinoma&#xD;
&#xD;
          -  High blood pressure, defined as &gt;140 millimeters of mercury (mm Hg) systolic blood&#xD;
             pressure or &gt;90 mm Hg diastolic blood pressure upon repeat confirmation&#xD;
&#xD;
          -  Cardiac arrhythmias or clinically significant ECG findings upon repeat confirmation by&#xD;
             the investigator&#xD;
&#xD;
          -  Corrected QT interval (QTc) &gt;450 milliseconds or deemed clinically significant by the&#xD;
             investigator&#xD;
&#xD;
          -  Family history of long QT syndrome&#xD;
&#xD;
          -  Blood loss or blood donation &gt;450 mL within 4 weeks of study drug dosing&#xD;
&#xD;
          -  History of sensitivity to drugs with chemical similarity to the study drug, its&#xD;
             components, or excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>moderately to severely active</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

